Month: July 2024

VEGFR-1 Inhibitors Market to Record an Exponential CAGR by 2031 | Here’s Why

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global VEGFR-1 Inhibitors Market– (By Drug Type (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, and Others), By Application (Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, and Other), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”

According to the latest research by InsightAce Analytic, the Global VEGFR-1 Inhibitors Market is predicted to grow with a CAGR of 7.0% during the forecast period of 2024-2031.

 

Download Free Demo Report with ToC and Excel Pviot: https://www.insightaceanalytic.com/request-sample/2552 

 

VEGFR-1 inhibitors are used to treat various types of cancers by inhibiting the vascular endothelial growth factor receptor-1, which plays a crucial role in angiogenesis and tumor growth. Increasing prevalence of cancer, advancements in targeted therapy, and rising awareness about cancer treatments are key factors driving the growth of the VEGFR-1 inhibitors market. 

Additionally, ongoing clinical trials and research activities to develop novel VEGFR-1 inhibitors, coupled with increasing healthcare expenditure, are expected to create lucrative opportunities for market players. Regulatory approvals and favorable reimbursement policies further support market growth. However, high treatment costs and potential side effects of VEGFR-1 inhibitors pose challenges to the market expansion. 

List of Prominent Players in the VEGFR-1 Inhibitors Market: 

  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Advenchen Laboratories, LLC
  • Sino Biopharmaceutical Limited
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Exelixis, Inc.
  • Ipsen S.A.
  • Pfizer Inc.
  • Hutchison China MediTech Limited (Hutchmed)
  • Mirati Therapeutics, Inc.
  • Eli Lilly and Company
  • Clovis Oncology, Inc.
  • Les Laboratoires Servier (Servier)
  • Pharma Mar, S.A.
  • F. Hoffmann-La Roche AG (Roche)
  • Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen)
  • Teva Pharmaceutical Industries Ltd. 

Market Dynamics: 

Drivers- 

The increasing prevalence of cancer globally, the rising demand for targeted therapies, and advancements in oncology research are primary drivers for the VEGFR-1 inhibitors market. Additionally, increasing healthcare expenditure and supportive regulatory environments are expected to boost market growth. The growing awareness and adoption of innovative cancer treatments are further contributing to the market’s expansion. 

Challenges: 

High treatment costs, potential side effects, and limited availability of VEGFR-1 inhibitors in developing regions are significant challenges for the market. Moreover, the stringent regulatory approval process for new drugs and the need for extensive clinical trials may impede market growth. The COVID-19 pandemic also disrupted clinical trials and healthcare services, affecting market dynamics. 

Regional Trends: 

North America is expected to dominate the VEGFR-1 inhibitors market, owing to a well-established healthcare infrastructure, high cancer prevalence, and significant R&D investments. Europe is anticipated to hold a substantial market share due to advanced medical research and favorable government initiatives. The Asia-Pacific region is projected to witness significant growth, driven by increasing healthcare awareness, improving healthcare facilities, and a rising patient population. Emerging economies in Latin America and the Middle East & Africa are also expected to contribute to market growth due to increasing cancer incidences and improving access to healthcare.

 

Curious About This Latest Version Of The Report? Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/2552

 

Recent Developments: 

  • In January 2022, Pfizer Inc. received FDA approval for a new VEGFR-1 inhibitor for the treatment of advanced renal cell carcinoma.
  • In March 2023, Novartis AG announced positive results from a phase III clinical trial of its investigational VEGFR-1 inhibitor for the treatment of non-small cell lung cancer. 

Segmentation of VEGFR-1 Inhibitors Market-

VEGFR-1 Inhibitors Market- By Drug Type:

  • Monoclonal Antibodies
  • Tyrosine Kinase Inhibitors
  • Other Drug Types

VEGFR-1 Inhibitors Market- By Application:

  • Renal Cell Carcinoma
  • Colorectal Cancer
  • Non-Small Cell Lung Cancer
  • Other Applications

VEGFR-1 Inhibitors Market- By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

VEGFR-1 Inhibitors Market- By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

 

For More Customization @

https://www.insightaceanalytic.com/customisation/2552

Media Contact
Company Name: InsightAce Analytic Pvt. Ltd
Contact Person: Diana D’Souza
Email: Send Email
Country: United States
Website: https://www.insightaceanalytic.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: VEGFR-1 Inhibitors Market to Record an Exponential CAGR by 2031 | Here\’s Why

The Boulder Group Arranges Sale of Net Lease Dollar General in Indiana

Randy Blankstein and Jimmy Goodman of The Boulder Group represented the seller in the transaction.

The Boulder Group, a net leased investment brokerage firm, completed the sale of a single tenant Dollar General located at 1055 Indiana 23 in Knox, Indiana for $1,625,000.

The 10,566 square foot building is located at the intersection of State Route 23 and State Route 8 in Knox, Indiana. Knox is positioned roughly halfway between Chicago and Fort Wayne. The location features ideal demographics for a Dollar General. There are over 14,100 people living within a seven-mile radius. The average household income within the same radius is $72,631. Additionally, the property benefits from its proximity Bass Lake which is a popular fishing and watersports destination for surrounding communities.

Randy Blankstein and Jimmy Goodman of The Boulder Group represented the seller in the transaction. The seller was a Midwest based developer and the buyer was a family partnership based in the Midwest.

There are fourteen years remaining on the Dollar General lease. The lease features 10% rental escalations in each of the four 5-year renewal option periods. The lease also features a corporate guaranty. Dollar General is an investment grade rated company with a Standard & Poor’s rating of BBB. Dollar General operated more than 12,500 stores in 43 states.

“New construction properties with long term leases to investment grade tenants with rental escalations are the most sought-after net lease product” said Randy Blankstein, President of The Boulder Group.  Jimmy Goodman of The Boulder Group, added, “The market for new construction net leased dollar stores remains active as they offer a stable investment at low price levels.”

About The Boulder Group

The Boulder Group is a boutique investment real estate service firm specializing in single tenant net lease properties. The firm provides a full range of brokerage, advisory, and financing services nationwide to a substantial and diversified client base, which includes high-net-worth individuals, developers, REITs, partnerships and institutional investment funds. Founded in 1997, the firm has arranged the acquisition and disposition of over $9 billion of single tenant net lease real estate transactions. From 2013-2023, the firm was ranked in the top 10 companies in the nation for single tenant retail transactions by both Real Capital Analytics and CoStar. The Boulder Group is headquartered in suburban Chicago and has an office in Denver.

www.bouldergroup.com

Media Contact
Company Name: The Boulder Group
Contact Person: Randy Blankstein
Email: Send Email
Phone: 8478816388
Address:3520 Lake Avenue Suite 203
City: Wilmette
State: Illinois
Country: United States
Website: https://www.bouldergroup.com/NNN-Properties-For-Sale.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Boulder Group Arranges Sale of Net Lease Dollar General in Indiana

LED Lighting Market worth $118.4 billion by 2029, growing at a CAGR of 8.5%

“LED Lighting Market”
The global LED Lighting Market in terms of revenue was estimated to be worth $78.9 billion in 2024 and is poised to reach $118.4 billion by 2029, growing at a CAGR of 8.5% during the forecast period.

According to a research report “LED Lighting Market by Product (Lamps, Luminaire), Application (Indoor, Outdoor), Installation (New, Retrofit), Sales Channel (Direct, retail, E-commerce) and Region (North America, Europe, APAC, Rest of the World) – Global Forecast to 2029” The global LED lighting market is projected to grow from USD 78.9 billion in 2024 to USD 118.4 billion by 2029, registering a CAGR of 8.5% during the forecast period. The LED lighting market is propelled by a combination of key drivers that have contributed to its widespread adoption globally. Energy efficiency stands out as a primary driver, with LED technology offering significant reductions in energy consumption compared to traditional lighting sources.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=201130554

Browse 171 market data Tables and 67 Figures spread through 271 Pages and in-depth TOC on “LED Lighting Market by Product (Lamps, Luminaire), Application (Indoor, Outdoor), Installation (New, Retrofit), Sales Channel (Direct, retail, E-commerce) and Region (North America, Europe, APAC, Rest of the World) – Global Forecast to 2029”

View detailed Table of Content here – https://www.marketsandmarkets.com/Market-Reports/led-lighting-market-201130554.html

LED Lighting Market

Environmental sustainability is another crucial factor, as LEDs produce less carbon emissions and contain no hazardous materials. Technological advancements and decreasing production costs have made LED lighting more affordable, further stimulating market growth. Government initiatives and regulations promoting energy-efficient solutions, along with an increasing awareness among consumers regarding the long-term cost savings and environmental benefits of LEDs, play a pivotal role in driving market demand. Moreover, the versatility of LED technology, providing options for smart lighting solutions and diverse applications across residential, commercial, and industrial sectors, contributes to the overall expansion and dynamism of the LED lighting market.

Lamps segment to lead the product segment during the forecast period.

LED lamps are expected to have a higher market share in the LED lighting market due to several compelling reasons. The versatility of LED lamps makes them suitable for a wide range of applications, from residential to commercial and industrial settings, contributing to their widespread adoption. LED lamps offer a variety of form factors, including traditional shapes and innovative designs, providing consumers with diverse options to fit different lighting needs. Additionally, the ease of retrofitting existing fixtures with LED lamps enhances their market appeal, allowing for a seamless transition to energy-efficient lighting. The efficiency and longevity of LED technology, characterized by lower energy consumption and extended lifespans compared to traditional lamps, result in substantial cost savings for consumers over time, further driving the preference for LED lamps. Furthermore, the integration of smart lighting features and compatibility with home automation systems positions LED lamps as part of the growing trend toward connected and intelligent lighting solutions, consolidating their dominance in the market.

By Installation, new installation is likely to record the highest growth rate during the forecast period.

New installations exhibit a higher CAGR in the LED lighting market within the installation type segment. The burgeoning demand for energy-efficient lighting solutions, coupled with advancements in LED technology, drives a preference for new installations over retrofitting existing systems. As construction and urbanization projects surge globally, there is an inherent need for modern and sustainable lighting infrastructures, positioning new installations as a pivotal growth driver. Additionally, stringent energy efficiency regulations and environmental awareness prompt a proactive approach in integrating LED lighting during the construction phase, further propelling the CAGR for new installations.

Asia Pacific is expected to account for the largest market share in the global LED lighting market by 2029.

The Asia-Pacific region is poised to have the largest share in the LED lighting market due to a convergence of influential factors. Rapid urbanization, particularly in countries like China and India, has led to a surge in demand for efficient lighting solutions, driving the adoption of LED technology. Government initiatives across the region, emphasizing energy efficiency and environmental sustainability, play a pivotal role in promoting LED lighting. Additionally, the sheer size of the population in Asia Pacific countries contributes to the scale of market adoption. As the region experiences economic growth, there is an increased capacity for investment in modern infrastructure, further boosting the demand for LED lighting in new construction projects.

Key Players

Signify Holding (Netherlands), Acuity Brands, Inc. (US), Cree Lighting USA LLC (US), ams OSRAM AG (Germany), LG Electronics (South Korea), Dialight (UK), Panasonic Corporation (Japan), Hubbell (US), Savant Systems, Inc. (US), and Zumtobel Group (Germany) are the major companies in the LED lighting market.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/led-lighting-market-201130554.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: LED Lighting Market worth $118.4 billion by 2029, growing at a CAGR of 8.5%

Plumbing Parts Market Projected to Hit USD 84.78 Billion by 2029, Unveiling Over $23 Billion Opportunities in the Next 6 Years – Exclusive Research Report by Arizton

“Plumbing Parts Market Research Report by Arizton”
Introducing Our Exclusive Subscription Model! Discover All the Benefits Today

According to the latest research report, the plumbing parts market 2024-2029 by Arizton Advisory & Intelligence, the market will grow at a CAGR of 5.42% during 2023-2029.   

 

Curious to Learn More About the Market: https://www.arizton.com/market-reports/plumbing-parts-market

 

Report Summary

Market Size (2029): USD 84.78 Billion 

Market Size (2023): USD 61.75 Billion 

CAGR (2023-2029): 5.42% 

Historic Year: 2019-2022 

Base Year: 2023

Forecast Year: 2024-2029

 

Subscribe us for more updates: https://www.arizton.com/subscription  

 

The plumbing industry is witnessing a significant surge in demand, propelled by various key factors. Renovation projects, fueled by the desire to modernize properties, particularly bathrooms and kitchens, are driving up the need for plumbing parts. Technological innovations like sensor faucets also contribute, requiring specialized components and sensors. Sustainability is another driver, with eco-friendly plumbing products necessitating specific parts. Additionally, the construction of luxury hotels and government investments in infrastructure projects further stimulate the market for plumbing parts, emphasizing the industry’s robust growth trajectory. 

 

Regional Insights  

North America accounted for 18.27% of the global plumbing parts market 2023. This growth is attributed to the increasing demand for water-efficient and sustainable plumbing products and the expanding construction industry in the US and Canada.  

The market growth in Europe is attributed to positive economic growth, an increase in housing units, and a rise in renovation projects. In addition, the growing tourism in countries such as Italy, Germany, and others further fuels the demand for plumbing parts in the region. APAC is witnessing rapid growth in the plumbing parts market due to its large population, rapid urbanization, and industrialization. The growing construction industry is also contributing to this growth. Countries like China, Japan, and South Korea are emerging as key markets, with consumers actively seeking innovative products. Latin America experiences a surge in demand for plumbing parts, driven by a burgeoning residential building construction sector, tourism development projects, an increased focus on renovation and maintenance, and evolving consumer lifestyles. This dynamic market presents significant opportunities for industry players. The demand for plumbing parts in the Middle East and Africa has been rising significantly due to increased investments in the hospitality sector, government spending on infrastructure projects, the oil and gas industry, and the growing disposable income of the region’s inhabitants. 

 

Key Merger & Acquisition and Technological Advances in the Plumbing Parts Market 

  • McWane acquired Tri-Seal Valve to serve a wide range of industrial fluid control applications, ultimately seeking to increase its profitability in the market. 
  • Morris Group launched a line of stainless-steel plumbing fixtures featuring cutting-edge innovations, such as touchless operation and an antimicrobial additive that effectively eliminates germs. 
  • NUPI INDUSTRIE ITALIANE S.p.A. partnered with Borealis to advance sustainability in pipe production by utilizing Bornewables polypropylene, thereby reducing its carbon footprint. 
  • In 2023, NUPI INDUSTRIE ITALIANE S.p.A. introduced 63mm electrofusion and spigot tees with incorporated adaptors, reducing assembly height and the need for multiple welds and improving efficiency. 
  • In September 2023, Reliance Worldwide Corporation announced a partnership with Galvin Engineering, aiming to create Lead Safe CliniMix Healthcare Thermostatic Mixing Valves (TMV) for the Australian plumbing industry. 

 

Recent Developments in the Global Plumbing Parts Market 

  • Uponor: In 2023, the company announced the production OF PEX pipe based on 100% chemically recycled raw material. Through this, the company diversifies its product portfolio and increases the volume of recycled materials in the market. 
  • Reliance Worldwide Corporation: In September 2023, the company announced a partnership with Galvin Engineering, aiming to create Lead Safe CliniMix Healthcare Thermostatic Mixing Valves (TMV) for the Australian plumbing industry. Through this collaboration, the company seeks to enhance its presence in the Australian market and expand its local manufacturing operations within the region. 
  • NUPI INDUSTRIE ITALIANE: In 2023, the company introduced 63mm electrofusion and spigot tees with incorporated adaptors, reducing assembly height and the need for multiple welds, improving efficiency. With this, the company aims to gain a competitive advantage in the plumbing parts market and increase its sales. 

 

Post-Purchase Benefit                        

  • 1hr of free analyst discussion                       
  • 10% off on customization     

 

Key Company Profiles 

  • Central States Industrial 
  • Finolex Industries Limited 
  • McWane 
  • Morris Group 
  • Mueller Industries 
  • NUPI INDUSTRIE ITALIANE S.p.A. 
  • Reliance Worldwide Corporation 
  • Turnkey Industrial Pipe & Supply Inc 
  • Uponor 
  • Prince Pipes and Fittings 
  • Masco Corporation 
  • Charlotte Pipe and Foundry 
  • TOTO 
  • CERA 
  • Hansgrohe Group 
  • Jaquar 
  • Kohler 
  • Ideal Standard 
  • Westlake Pipe & Fittings 
  • Elkay Manufacturing Company 
  • Guangdong Huayi Plumbing Fittings 
  • Jacuzzi 
  • Globe Union Industrial 
  • Roca Sanitario 
  • Proflo 
  • Geberit AG 
  • Moen 
  • Novanative 
  • Multipipe 
  • Flair-It 
  • Giacomini 
  • VNE Corporation 
  • Zhejiang Valogin Technology 
  • Viega 
  • Caleffi 
  • HotTubOutpost 
  • Tech Tubes & Fittings 
  • Tigre USA 

 

Market Segmentation 

Product 

  • Pipes & Tubes 
  • Valves 
  • Fittings 
  • Manifolds 

 

End-users 

  • Residential 
  • Non- Residential 

 

Applications 

  • Faucets 
  • Sinks, Toilets & Other 
  • Showerhead 
  • Bathtubs 

 

Geography 

APAC 

  • China 
  • India 
  • Japan 
  • Indonesia 
  • South Korea 
  • Australia 

Europe 

  • Germany  
  • France 
  • The UK 
  • Italy 
  • Spain 
  • Russia 
  • Poland 

North America 

  • The US 
  • Canada 

Middle East & Africa 

  • Saudi Arabia 
  • The UAE 
  • Turkey 
  • South Africa 

Latin America 

  • Brazil 
  • Mexico 
  • The Rest of Latin America 

 

Key Questions Answered in the Report:    

How big is the plumbing parts market? 

What is the growth rate of the global plumbing parts market? 

Which region dominates the global plumbing parts market share? 

What are the significant trends in the plumbing parts market? 

Who are the key players in the global plumbing parts market?  

 

Check Out Some of the Top top-selling Research Reports:     

U.S. Smart Bathroom Market – Industry Outlook & Forecast 2022-2027

https://www.arizton.com/market-reports/us-smart-bathroom-market

Door Closer and Exit Devices Market – Global Outlook And Forecast 2023-2028

https://www.arizton.com/market-reports/door-closer-market-size-analysis-report

 

Why Arizton?                 

100% Customer Satisfaction                 

24×7 availability – we are always there when you need us                 

200+ Fortune 500 Companies trust Arizton’s report                 

80% of our reports are exclusive and first in the industry                 

100% more data and analysis                 

1500+ reports published till date                  

 

About US:                                                      

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                    

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                     

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                           

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040
Country: United States
Website: https://www.arizton.com/market-reports/plumbing-parts-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Plumbing Parts Market Projected to Hit USD 84.78 Billion by 2029, Unveiling Over $23 Billion Opportunities in the Next 6 Years – Exclusive Research Report by Arizton

Roaring Kitty Expands Horizons: Key Stocks to Watch as Influencer Shakes Up Market: CHWY, DYAI, WOOF, VTAK, INBS

The influencer ‘Roaring Kitty’ shook the stock markets with the ‘meme stock’ phenomenon, with GameStop, Inc. (NYSE: GME) becoming his most notable trade. Meme stocks have generated substantial wealth for traders, and it seems Roaring Kitty is now broadening his scope. This feature offers insight into the stock’s worth monitoring in light of Roaring Kitty’s latest moves.

Chewy Inc. (NASDAQ: CHWY): Chewy experienced significant volatility on July 1 after a regulatory filing revealed that Roaring Kitty acquired a 6.6% stake. Roaring Kitty bought 9 million shares of the pet retailer, totaling over $261 million at a closing price of $29.05 per share on June 28. This made him the third-largest shareholder, with the stock gaining over 20% before markets opened on July 1. 

Dyadic International Inc. (NASDAQ: DYAI): Dyadic International, a leader in cell culture solutions, announced a strategic partnership with Proliant Health and Biologicals (PHB) last month. PHB will provide $1.5 million upfront for developing high-volume, cost-effective cell culture products set to enter the $6 billion serum albumin market in the first half of 2025. Zacks SmallCap valued Dyadic at $9 a share in a July 1 report. Read entire report now. 

Petco Health and Wellness Company Inc. (NASDAQ: WOOF): Petco released its 2023 ESG report last month, highlighting its commitment to pet owners, pets, and employees. The Petco Love initiative found homes for 142,924 pets in the 2023 fiscal year and donated $33.5 million to 2,000 animal welfare organizations and shelters. Petco also expanded its in-store veterinary hospitals to over 280 locations. 

Catheter Precision Inc. (NYSE AMERICAN: VTAK) saw its stock surge 43.58% on July 1, reaching an intraday high of $0.84 per share before pulling back over 50% to $0.38, creating a potential buying opportunity. This followed the announcement of unaudited revenues for the fiscal quarter and six months ended June 30, 2024. The company reported sales of its innovative LockeT and VIVO products. The VIVO system, a non-invasive 3D imaging technology, enhances the efficiency of ventricular ablation, aligning with the company’s expansion strategy. Read Entire Update Now!

Catheter Precision Inc. (NYSE AMERICAN: VTAK) saw its stock surge 43.58% on July 1, reaching an intraday high of $0.84 per share before pulling back over 50% to $0.38, creating a potential buying opportunity. This followed the announcement of unaudited revenues for the fiscal quarter and six months ended June 30, 2024. The company reported sales of its innovative LockeT and VIVO products. The VIVO system, a non-invasive 3D imaging technology, enhances the efficiency of ventricular ablation, aligning with the company’s expansion strategy. Read Entire Update Now!

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Roaring Kitty Expands Horizons: Key Stocks to Watch as Influencer Shakes Up Market: CHWY, DYAI, WOOF, VTAK, INBS

Ischemic Stroke Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Market Impact by DelveInsight | Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharma, Genentech, Inc., NoNO, Pharming

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Ischemic Stroke pipeline constitutes 50+ key companies continuously working towards developing 55+ Ischemic Stroke treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Ischemic Stroke Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ischemic Stroke Market.

 

The Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Ischemic Stroke Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Ischemic Stroke treatment therapies with a considerable amount of success over the years. 

  • Ischemic Stroke companies working in the treatment market are TargED Biopharmaceuticals, Saillant Therapeutics, AbbVie, Revalesio Corporation, Biogen, Acticor Biotech, ZZ Biotech, GNT Pharma, Athersys, Inc., Acticor Biotech, Lumosa Therapeutics, Avilex Pharma, and others, are developing therapies for the Ischemic Stroke treatment 

  • Emerging Ischemic Stroke therapies in the different phases of clinical trials are- Microlyse, ST-01, Elezanumab, RNS60, BIIB131, Glenzocimab, 3K3A-APC, Nelonemdaz, MultiStem, Glenzocimab, LT3001, AVLX-144, and others are expected to have a significant impact on the Ischemic Stroke market in the coming years.   

  • In January 2024, Aruna Bio has revealed intentions to commence a Phase I/II clinical trial of AB126 for treating acute ischemic stroke by the first half of 2024. This decision follows the clearance of the company’s investigational new drug (IND) application by the US Food and Drug Administration (FDA) for its lead program, AB126. This milestone represents the first IND approval for Aruna Bio’s platform. 

 

Ischemic Stroke Overview

An ischemic stroke, also known as a brain attack, happens when a blood artery in the brain breaks or when something stops the blood supply to a portion of the brain. Either way, certain brain regions suffer harm or even die. A stroke can result in death, long-term incapacity, or permanent brain damage.

 

Get a Free Sample PDF Report to know more about Ischemic Stroke Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/ischemic-stroke-pipeline-insight

 

Emerging Ischemic Stroke Drugs Under Different Phases of Clinical Development Include:

  • Microlyse: TargED Biopharmaceuticals

  • ST-01: Saillant Therapeutics

  • Elezanumab: AbbVie

  • RNS60: Revalesio Corporation

  • BIIB131: Biogen

  • Glenzocimab: Acticor Biotech

  • 3K3A-APC: ZZ Biotech

  • Nelonemdaz: GNT Pharma

  • MultiStem: Athersys, Inc.

  • Glenzocimab: Acticor Biotech

  • Elezanumab: AbbVie

  • LT3001: Lumosa Therapeutics

  • AVLX-144: Avilex Pharma

 

Ischemic Stroke Route of Administration

Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Intravenous

  • Subcutaneous

  • Parenteral

  • Topical

 

Ischemic Stroke Molecule Type

Ischemic Stroke Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

 

Ischemic Stroke Pipeline Therapeutics Assessment

  • Ischemic Stroke Assessment by Product Type

  • Ischemic Stroke By Stage and Product Type

  • Ischemic Stroke Assessment by Route of Administration

  • Ischemic Stroke By Stage and Route of Administration

  • Ischemic Stroke Assessment by Molecule Type

  • Ischemic Stroke by Stage and Molecule Type

 

DelveInsight’s Ischemic Stroke Report covers around 55+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Ischemic Stroke product details are provided in the report. Download the Ischemic Stroke pipeline report to learn more about the emerging Ischemic Stroke therapies

 

Some of the key companies in the Ischemic Stroke Therapeutics Market include:

Key companies developing therapies for Ischemic Stroke are – Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharmaceutical Co., Ltd., Genentech, Inc., NoNO Inc., Pharming Technologies B.V., Biogen, Athersys, Inc., Tarveda Therapeutics, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Avilex Pharma, Lumosa Therapeutics, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals, SanBio, ZZ Biotech, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon Pharmaceuticals, Primary Peptides, TMS, Tasly Pharmaceutical, Pharmazz and others.

 

Ischemic Stroke Pipeline Analysis:

The Ischemic Stroke pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Ischemic Stroke with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ischemic Stroke Treatment.

  • Ischemic Stroke key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ischemic Stroke market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Ischemic Stroke drugs and therapies

 

Ischemic Stroke Pipeline Market Drivers

  • Rising incidence of Acute Ischemic Stroke, increasing prevalence of lifestyle associated disorders such as diabetes and hypertension, rising geriatric population are some of the important factors that are fueling the Ischemic Stroke Market.

 

Ischemic Stroke Pipeline Market Barriers

  • However, challenges associated with the clinical research, challenges with the diagnosis of AIS and other factors are creating obstacles in the Ischemic Stroke Market growth.

 

Scope of Ischemic Stroke Pipeline Drug Insight    

  • Coverage: Global

  • Key Ischemic Stroke Companies: TargED Biopharmaceuticals, Saillant Therapeutics, AbbVie, Revalesio Corporation, Biogen, Acticor Biotech, ZZ Biotech, GNT Pharma, Athersys, Inc., Acticor Biotech, Lumosa Therapeutics, Avilex Pharma, and others

  • Key Ischemic Stroke Therapies: Microlyse, ST-01, Elezanumab, RNS60, BIIB131, Glenzocimab, 3K3A-APC, Nelonemdaz, MultiStem, Glenzocimab, LT3001, AVLX-144, and others

  • Ischemic Stroke Therapeutic Assessment: Ischemic Stroke current marketed and Ischemic Stroke emerging therapies

  • Ischemic Stroke Market Dynamics: Ischemic Stroke market drivers and Ischemic Stroke market barriers 

 

Request for Sample PDF Report for Ischemic Stroke Pipeline Assessment and clinical trials

 

Table of Contents

1. Ischemic Stroke Report Introduction

2. Ischemic Stroke Executive Summary

3. Ischemic Stroke Overview

4. Ischemic Stroke- Analytical Perspective In-depth Commercial Assessment

5. Ischemic Stroke Pipeline Therapeutics

6. Ischemic Stroke Late Stage Products (Phase II/III)

7. Ischemic Stroke Mid Stage Products (Phase II)

8. Ischemic Stroke Early Stage Products (Phase I)

9. Ischemic Stroke Preclinical Stage Products

10. Ischemic Stroke Therapeutics Assessment

11. Ischemic Stroke Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Ischemic Stroke Key Companies

14. Ischemic Stroke Key Products

15. Ischemic Stroke Unmet Needs

16 . Ischemic Stroke Market Drivers and Barriers

17. Ischemic Stroke Future Perspectives and Conclusion

18. Ischemic Stroke Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ischemic Stroke Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Market Impact by DelveInsight | Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharma, Genentech, Inc., NoNO, Pharming

Oakio Unveils Superior Anti-Corrosion and Insect-Proof WPC Beam

Oakio, a leading innovator in wood-plastic composite (WPC) materials, announces the launch of its groundbreaking WPC Beam, designed specifically to address the persistent challenges of corrosion and insect infestation that plague traditional wood products. This revolutionary product promises to set a new standard in the construction and landscaping industries, offering unmatched durability and longevity. 

Unparalleled Anti-Corrosion Performance 

Oakio’s WPC Beam has superior resistance to corrosion. The secret lies in the unique composition of the WPC material, which combines recycled wood fibers and high-quality plastic polymers with co-extrusion technology. This blend not only replicates the natural look and feel of wooden board but also imbues the beam with exceptional resistance to moisture. Therefore, Oakio’s WPC Beam can remain unaffected by rain, humidity, and temperature fluctuations, ensuring that it retains its strength and aesthetic appeal for years.

Innovative Insect-Proof Technology 

Oakio’s WPC Beam tackles the common issue of insect damage found in traditional wood with its innovative insect-proof technology. The wood composite material used in Oakio’s beams is inherently resistant to insect infestation. Additionally, Oakio incorporates advanced additives into the manufacturing process, further enhancing the material’s resistance to insects. This means that structures built with Oakio’s WPC Beams remain free from the damage typically caused by termites and other wood-destroying insects. 

Eco-Friendly and Sustainable Solution

In line with Oakio’s dedication to sustainability, WPC beam is meticulously crafted from eco-friendly materials, comprising 55% oak wood fiber, 35% plastic resin, and 10% additives. This commitment to environmental responsibility ensures that each WPC beam delivers outstanding quality and performance while supporting a more sustainable future.

Build Protected Outdoor Oasis with Oakio WPC Beam

Oakio’s revolutionary WPC Beam with superior anti-corrosion and insect-proof properties is set to transform the construction and landscaping industries. By addressing the critical pain points associated with traditional wood, Oakio offers a product that not only ensures longevity and durability but also promotes environmental sustainability. Whether for residential or commercial projects, Oakio’s WPC Beam stands as the ultimate choice for builders and homeowners seeking reliable, low-maintenance, and eco-friendly building materials. 

For more information about Oakio WPC Beam and other Oakio products, visit www.oakio.com.

Media Contact
Company Name: Oakio
Contact Person: Juno Zhong
Email: Send Email
Country: China
Website: https://www.oakio.com/

Complement 3 Glomerulopathy Pipeline Overview 2024: FDA Approvals and Clinical Trials by DelveInsight | ChemoCentryx, Novartis, Omeros Corporation, Apellis Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Complement 3 Glomerulopathy pipeline constitutes 3+ key companies continuously working towards developing 3+ Complement 3 Glomerulopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Complement 3 Glomerulopathy Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Complement 3 Glomerulopathy Market.

 

The Complement 3 Glomerulopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Complement 3 Glomerulopathy Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Complement 3 Glomerulopathy treatment therapies with a considerable amount of success over the years. 

  • Complement 3 Glomerulopathy companies working in the treatment market are Q32 Bio Inc., Novartis, Kira Pharmacenticals, NovelMed Therapeutics, Apellis Pharmaceuticals, Novartis, Amyndas Pharmaceuticals, and others, are developing therapies for the Complement 3 Glomerulopathy treatment 

  • Emerging Complement 3 Glomerulopathy therapies in the different phases of clinical trials are- ADX-097, iptacopan, KP104, NM8074, Pegcetacoplan(APL-2), LNP023, AMY-10, iptacopan, and others are expected to have a significant impact on the Complement 3 Glomerulopathy market in the coming years.   

  • In December 2023, Kira Pharmaceuticals is dedicated to advancing KP104 as an innovative therapy for patients suffering from PNH and other diseases mediated by complement. The interim findings from the Phase 2 study in complement-naïve PNH patients represent a significant advancement in the development of KP104 as a safe and effective treatment for PNH, aiming to meet critical medical needs that are currently unmet. These results also establish a proof-of-concept and provide a robust basis for future clinical trials targeting other complement-mediated conditions, including IgA nephropathy (IgAN), complement 3 glomerulopathy (C3G), and thrombotic microangiopathies associated with systemic lupus erythematosus (SLE-TMA).

 

Complement 3 Glomerulopathy Overview

Complement 3 Glomerulopathy (C3G) is a rare kidney disorder characterized by abnormal deposits of complement protein C3 in the glomeruli, the tiny blood vessels in the kidneys that filter waste from the blood. The disorder is associated with dysregulation of the complement system, a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear pathogens and damaged cells.

 

Get a Free Sample PDF Report to know more about Complement 3 Glomerulopathy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/complement-3-glomerulopathy-pipeline-insight

 

Emerging Complement 3 Glomerulopathy Drugs Under Different Phases of Clinical Development Include:

  • NM8074: NovelMed Therapeutics

  • Pegcetacoplan(APL-2): Apellis Pharmaceuticals

  • LNP023: Novartis Pharmaceuticals

  • AMY-10: Amyndas Pharmaceuticals

 

Complement 3 Glomerulopathy Route of Administration

Complement 3 Glomerulopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Complement 3 Glomerulopathy Molecule Type

Complement 3 Glomerulopathy Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

  • Product Type

 

Complement 3 Glomerulopathy Pipeline Therapeutics Assessment

  • Complement 3 Glomerulopathy Assessment by Product Type

  • Complement 3 Glomerulopathy By Stage and Product Type

  • Complement 3 Glomerulopathy Assessment by Route of Administration

  • Complement 3 Glomerulopathy By Stage and Route of Administration

  • Complement 3 Glomerulopathy Assessment by Molecule Type

  • Complement 3 Glomerulopathy by Stage and Molecule Type

 

DelveInsight’s Complement 3 Glomerulopathy Report covers around 3+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Complement 3 Glomerulopathy product details are provided in the report. Download the Complement 3 Glomerulopathy pipeline report to learn more about the emerging Complement 3 Glomerulopathy therapies

 

Some of the key companies in the Complement 3 Glomerulopathy Therapeutics Market include:

Key companies developing therapies for Complement 3 Glomerulopathy are – ChemoCentryx, Novartis Pharmaceuticals, Omeros Corporation, Apellis Pharmaceuticals, and others.

 

Complement 3 Glomerulopathy Pipeline Analysis:

The Complement 3 Glomerulopathy pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Complement 3 Glomerulopathy with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Complement 3 Glomerulopathy Treatment.

  • Complement 3 Glomerulopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Complement 3 Glomerulopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Complement 3 Glomerulopathy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Complement 3 Glomerulopathy drugs and therapies

 

Complement 3 Glomerulopathy Pipeline Market Strengths

  • The emerging market of C3G possesses several key players such as Apellis Pharmaceuticals, ChemoCentryx, and Novartis Pharmaceuticals.

  • The advent of novel biomarkers in the near future can shed some light on the pathophysiology of the disease, which may enhance the diagnosis of the indication.

 

Complement 3 Glomerulopathy Pipeline Market Opportunities

  • Several organizations such as WeC3G, National Kidney Foundation (NKF), American Society of Nephrology (ASN), Kidney Disease: International Global Organization (KDIGO),Japanese Society of Nephrology (JSN), etc. are actively working to provide information and awareness of the disorder.

 

Scope of Complement 3 Glomerulopathy Pipeline Drug Insight    

  • Coverage: Global

  • Key Complement 3 Glomerulopathy Companies: Q32 Bio Inc., Novartis, Kira Pharmacenticals, NovelMed Therapeutics, Apellis Pharmaceuticals, Novartis, Amyndas Pharmaceuticals, and others

  • Key Complement 3 Glomerulopathy Therapies: ADX-097, iptacopan, KP104, NM8074, Pegcetacoplan(APL-2), LNP023, AMY-10, iptacopan, and others

  • Complement 3 Glomerulopathy Therapeutic Assessment: Complement 3 Glomerulopathy current marketed and Complement 3 Glomerulopathy emerging therapies

  • Complement 3 Glomerulopathy Market Dynamics: Complement 3 Glomerulopathy market drivers and Complement 3 Glomerulopathy market barriers 

 

Request for Sample PDF Report for Complement 3 Glomerulopathy Pipeline Assessment and clinical trials

 

Table of Contents

1. Complement 3 Glomerulopathy Report Introduction

2. Complement 3 Glomerulopathy Executive Summary

3. Complement 3 Glomerulopathy Overview

4. Complement 3 Glomerulopathy- Analytical Perspective In-depth Commercial Assessment

5. Complement 3 Glomerulopathy Pipeline Therapeutics

6. Complement 3 Glomerulopathy Late Stage Products (Phase II/III)

7. Complement 3 Glomerulopathy Mid Stage Products (Phase II)

8. Complement 3 Glomerulopathy Early Stage Products (Phase I)

9. Complement 3 Glomerulopathy Preclinical Stage Products

10. Complement 3 Glomerulopathy Therapeutics Assessment

11. Complement 3 Glomerulopathy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Complement 3 Glomerulopathy Key Companies

14. Complement 3 Glomerulopathy Key Products

15. Complement 3 Glomerulopathy Unmet Needs

16 . Complement 3 Glomerulopathy Market Drivers and Barriers

17. Complement 3 Glomerulopathy Future Perspectives and Conclusion

18. Complement 3 Glomerulopathy Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Complement 3 Glomerulopathy Pipeline Overview 2024: FDA Approvals and Clinical Trials by DelveInsight | ChemoCentryx, Novartis, Omeros Corporation, Apellis Pharma

Chronic Refractory Cough Pipeline Analysis 2024: FDA Approvals and Emerging Therapies by DelveInsight | Genentech, Trevi Therapeutics, Guangdong Hengrui Pharma, Ltd, Bellus Health, Merck

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Chronic Refractory Cough pipeline constitutes key companies continuously working towards developing Chronic Refractory Cough treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Chronic Refractory Cough Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Refractory Cough Market.

 

The Chronic Refractory Cough Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Chronic Refractory Cough Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Chronic Refractory Cough treatment therapies with a considerable amount of success over the years. 

  • Chronic Refractory Cough companies working in the treatment market are Nocion Therapeutics, Genentech, Inc., Trevi Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd, Bellus Health Inc, Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., and others, are developing therapies for the Chronic Refractory Cough treatment 

  • Emerging Chronic Refractory Cough therapies in the different phases of clinical trials are- NOC-100, GDC-6599, Haduvio, HRS-2261, BLU-5937, MK-7264 (gefapixant), Orvepitant Maleate, Camlipixant (BLU-5937), AX-8, ADX-629, GDC-6599, and others are expected to have a significant impact on the Chronic Refractory Cough market in the coming years.

  • In December 2023, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, has announced the start of its Phase 2b CORAL clinical trial. The trial will evaluate three doses of Haduvio™ (oral nalbuphine ER) against a placebo in around 160 patients with idiopathic pulmonary fibrosis (IPF) who have chronic cough. This Phase 2b trial follows the successful results of the Phase 2a CANAL trial, which showed a significant 75.1% reduction in daytime cough frequency, a 52.5% improvement over placebo (p<0.0001). Haduvio is being developed for chronic cough in IPF, refractory chronic cough (RCC), and prurigo nodularis.

  • In June 2023, Bellus Health Inc. and GSK plc declared Bellus has been fully acquired by GSK. Camlipixant, a potentially best-in-class and highly selective P2X3 antagonist that is presently in phase III development for the first-line treatment of adult patients with refractory chronic cough, is part of the Bellus purchase.

  • In January 2023, A Phase III, 24-week, randomized, double-blind, placebo-controlled, parallel-arm effectiveness and safety trial was started by Bellus Health Inc. with an open-label extension of BLU-5937 for adult participants with refractory chronic cough, including chronic cough that is not explained. The experiment is expected to conclude with 675 participants by July 2025.  

 

Chronic Refractory Cough Overview

A cough that lasts longer than eight weeks is referred to as chronic, and many individuals with chronic refractory cough have coughs that last considerably longer. Furthermore, the illness is known as chronic refractory cough when the reason of the persistent cough cannot be found or the cough continues even after receiving the best care possible for any related conditions.

 

Get a Free Sample PDF Report to know more about Chronic Refractory Cough Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-refractory-cough-pipeline-insight

 

Emerging Chronic Refractory Cough Drugs Under Different Phases of Clinical Development Include:

  • NOC-100: Nocion Therapeutics

  • GDC-6599: Genentech, Inc.

  • Haduvio: Trevi Therapeutics

  • HRS-2261: Guangdong Hengrui Pharmaceutical Co., Ltd

  • BLU-5937: Bellus Health Inc

  • MK-7264 (gefapixant): Merck & Co/Kyorin Pharmaceuticals

  • Orvepitant Maleate: NeRRe Therapeutics

  • Camlipixant (BLU-5937): Bellus Health/GSK

  • AX-8: Axalbion

  • ADX-629: Aldeyra Therapeutics

  • GDC-6599: Genentech, Inc.

 

Route of Administration

Chronic Refractory Cough pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Intravenous

  • Subcutaneous

  • Parenteral

  • Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

 

Chronic Refractory Cough Pipeline Therapeutics Assessment

  • Chronic Refractory Cough Assessment by Product Type

  • Chronic Refractory Cough By Stage and Product Type

  • Chronic Refractory Cough Assessment by Route of Administration

  • Chronic Refractory Cough By Stage and Route of Administration

  • Chronic Refractory Cough Assessment by Molecule Type

  • Chronic Refractory Cough by Stage and Molecule Type

 

DelveInsight’s Chronic Refractory Cough Report covers around products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Chronic Refractory Cough product details are provided in the report. Download the Chronic Refractory Cough pipeline report to learn more about the emerging Chronic Refractory Cough therapies

 

Some of the key companies in the Chronic Refractory Cough Therapeutics Market include:

Key companies developing therapies for Chronic Refractory Cough are – Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, Shionogi, Axalbion, Aldeyra Therapeutics and others.

 

Chronic Refractory Cough Pipeline Analysis:

The Chronic Refractory Cough pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Refractory Cough with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Refractory Cough Treatment.

  • Chronic Refractory Cough key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Chronic Refractory Cough Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Refractory Cough market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Chronic Refractory Cough drugs and therapies

 

Chronic Refractory Cough Pipeline Market Drivers

  • Increasing Prevalence of cough, growing demand for treatment for Chronic Refractory Cough are some of the important factors that are fueling the Chronic Refractory Cough Market.

 

Chronic Refractory Cough Pipeline Market Barriers

  • However, lack of awareness, lack of availability of specific biomarkers that are useful for accurate and timely diagnosis and other factors are creating obstacles in the Chronic Refractory Cough Market growth.

 

Scope of Chronic Refractory Cough Pipeline Drug Insight    

  • Coverage: Global

  • Key Chronic Refractory Cough Companies: Nocion Therapeutics, Genentech, Inc., Trevi Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd, Bellus Health Inc, Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., and others

  • Key Chronic Refractory Cough Therapies: NOC-100, GDC-6599, Haduvio, HRS-2261, BLU-5937, MK-7264 (gefapixant), Orvepitant Maleate, Camlipixant (BLU-5937), AX-8, ADX-629, GDC-6599, and others

  • Chronic Refractory Cough Therapeutic Assessment: Chronic Refractory Cough current marketed and Chronic Refractory Cough emerging therapies

  • Chronic Refractory Cough Market Dynamics: Chronic Refractory Cough market drivers and Chronic Refractory Cough market barriers 

 

Request for Sample PDF Report for Chronic Refractory Cough Pipeline Assessment and clinical trials

 

Table of Contents

1. Chronic Refractory Cough Report Introduction

2. Chronic Refractory Cough Executive Summary

3. Chronic Refractory Cough Overview

4. Chronic Refractory Cough- Analytical Perspective In-depth Commercial Assessment

5. Chronic Refractory Cough Pipeline Therapeutics

6. Chronic Refractory Cough Late Stage Products (Phase II/III)

7. Chronic Refractory Cough Mid Stage Products (Phase II)

8. Chronic Refractory Cough Early Stage Products (Phase I)

9. Chronic Refractory Cough Preclinical Stage Products

10. Chronic Refractory Cough Therapeutics Assessment

11. Chronic Refractory Cough Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Refractory Cough Key Companies

14. Chronic Refractory Cough Key Products

15. Chronic Refractory Cough Unmet Needs

16 . Chronic Refractory Cough Market Drivers and Barriers

17. Chronic Refractory Cough Future Perspectives and Conclusion

18. Chronic Refractory Cough Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Refractory Cough Pipeline Analysis 2024: FDA Approvals and Emerging Therapies by DelveInsight | Genentech, Trevi Therapeutics, Guangdong Hengrui Pharma, Ltd, Bellus Health, Merck

Construction Chemicals Market to Gain 8.6% CAGR by 2031 Pioneering the Path to Sustainable Construction Solutions

“Skyquest Technology”
Construction Chemicals Market Size, Share, Growth Analysis, By Type(Concrete Admixture (Mineral Admixture {Fly Ash, Silica Fume, Rice Husk Ash, Granulated Blast Furnace Slag}), By End User(Residential, Industrial/Commercial, Infrastructure, Others), By Region – Industry Forecast 2024-2031

Construction Chemicals Market size was valued at USD 27.74 billion in 2022 and is poised to grow from USD 30.1 billion in 2023 to USD 37.55 billion by 2031, growing at a CAGR of 8.6% in the forecast period (2024-2031).

Notable trends in the building chemicals market indicate the changing demands of the construction sector and improvements in materials and technologies. An emerging trend in the building chemicals industry is the growing use of ecologically friendly and sustainable solutions. Environmentally friendly construction chemicals are in greater demand due to green building approaches which also boost energy efficiency while strictly abiding eco-friendly regulations. Consequently, there is a growing necessity for high-performance concrete admixture. Also, it is worth noting how innovations in coating solutions shape market trends. This way, modern coatings provide protection shields which repel bad weather conditions, UV rays, as well as chemical damage from the surface of buildings.

Download a detailed overview:

https://www.skyquestt.com/sample-request/construction-chemicals-market

Eco-Innovation in Concrete Jungle

Global construction chemicals market competition includes major competitors including Dow Inc., Sika AG, and BASF SE. These firms are increasingly focusing on strategic mergers/acquisitions alongside new product development so as to enhance their competitive position within the market. Due to the quick pace at which they are urbanizing and building infrastructure, emerging markets offer enormous growth opportunities, notably in Asia-Pacific region. Additionally, firms have increased their expenditure in the production of green products that met environmental standards as it is what clients want or required by law. Technological developments and the demand for high-performance, reasonably priced solutions fuel fierce rivalry, which propels ongoing R&D efforts in the sector.

Innovative Foundations and Strategic Maneuvers in Construction Chemicals Industry

Leading companies in the building chemicals business, including Dow Inc., Sika AG, and BASF SE, dominate the competitive landscape of the global market. These businesses use strategic mergers and acquisitions, together with innovative product development, to both preserve and grow their market share. The Asia-Pacific region presents noteworthy prospects due to its swift urbanisation and tremendous infrastructure expansion.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/construction-chemicals-market

There’s an increase in spending by companies on green products aiming at meeting legal standards as well as catering for the shifting consumer needs. Intense competition characterized by technological advancement and demand of quality-priced products forces businesses in the industry to incur huge costs in continuous product research and development.

Sika AG’s Strategic Alliance Pioneering the Asia-Pacific Construction Frontier

Consider BASF SE’s acquisition of Chemetall concerning the competitive environment discussed here. This acquisition increased BASF SE’s presence within the specialized chemicals sector relating to construction. Sika AG is concentrating on expanding markets that have high growth potential—its alliances target such firms as large constructors in the Asia Pacific area. The production of new plastics intended for eco-house designs corresponds to Dow Inc.’s new trend of creating stuff, especially houses, that are sustainable environmentally. BASF SE highlights the importance of product innovation by releasing new concrete binders that will last longer and provide better performance. This serves as an example of how market leaders in construction chemicals use controlled risk taking, state-of-the-art methods, as well as eco-friendly options to maintain their competitive advantage.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/construction-chemicals-market

Ever-Evolving Landscape of Sustainable Construction Chemicals and Market Dynamics

The building chemicals market is changing; a new shift in the construction market towards sustainability and innovation seems to follow suit. The industry is changing due to green construction initiatives, which are increasing demand for environmentally friendly products including high-performance concrete admixtures and sophisticated coatings. Prominent entities like as Dow Inc., Sika AG, and BASF SE strategically manoeuvre within this ever-changing landscape via mergers, acquisitions, and unrelenting research and development. Amidst increasing urbanisation, emerging economies, particularly in Asia-Pacific, present a favourable environment for growth. Investing in sustainable technologies becomes essential as customer preferences change and regulatory constraints increase.

Related Reports:

Digital Transformation Market

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/construction-chemicals-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Construction Chemicals Market to Gain 8.6% CAGR by 2031 Pioneering the Path to Sustainable Construction Solutions